Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
US7253198B2 · kind B2 · utility
52Cited by
5References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2003 |
| Grant date | Aug 7, 2007 |
| Priority date | — |
| Expiry date | Jul 27, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.